Effects of isoprenoid analogues of SDB-ethylenediamine on multidrug resistant tumor cells alone and in combination with chemotherapeutic drugs

Journal of Medicinal Chemistry

Volumn 45, Issue 24, 2002, Pages 5330-5339

  Sidorova, Tatyana A ^a   Nigmatov, Albert G ^b   Kakpakova, Eugenia S ^c   Stavrovskaya, Alla A ^c   Gerassimova, Galina K ^a   Shtil, Alexander A ^c   Serebryakov, Edward P ^b  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^b N D ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ISOPRENOID; N,N' BIS(3,4 DIMETHOXYBENZYL) N SOLANESYLETHYLENEDIAMINE; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MAMMAL; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CELL LINE; CRICETINAE; CYTARABINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ETHYLENEDIAMINES; FIBROBLASTS; HUMANS; P-GLYCOPROTEIN; POLYENES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0037153214     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm011010t     Document Type: Article

References (53)

1. Roninson, I. B. P-Glycoprotein-mediated drug resistance: Puzzles and perspectives. In Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells; Roninson, I. B., Ed.; Plenum Press: New York and London, 1991; pp 395-402.
2. Dano, K. Active outward transport of daunorubicin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 1973, 323, 466-483.
3. Gottesman, M. M.; Pastan, I.; Ambudkar, S. V. P-Glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 1996, 6, 610-617.
4. Volm, M. Multidrug resistance and its reversal. Anticancer Res. 1998, 18 (4C), 2905-2918.
5. Sheehan, D.; Meade, G. Chemical modification of chemotherapy resistance. Biochem. Soc. Trans. 2000, 28, 27-32.
6. Dorr, R.; Karanes, C.; Spier, C.; Grogan, T.; Moore, J.; Weinberger, B.; Schiller, G.; Pearce, T.; Litchman, M.; Dalton, W.; Roe, D.; List, A. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol. 2001, 19, 1589-1599.
7. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981, 41, 1967-1972.
8. Yusa, K.; Tsuruo, T. Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and specific transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989, 49, 5002-5006.
9. Safa, A. R. Photoaffinity labeling of multidrug resistance-related P-glycoprotein with photoactive analogues of verapamil. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7187-7191.
10. Klopman, G.; Srivastava, S.; Kolossvary, I.; Epand, R. F.; Ahmed, N.; Epand, R. M. Structure-activity study and design of multidrug-resistant reversal compounds by a computer automated structure evaluation methodology. Cancer Res. 1992, 52, 4121-4129.
11. Abraham, I.; Hester, J. B. Use of amines to sensitize multidrug-resistant cells. PCT Int. Appl. WO 92/18089 1992; Chem. Abstr. 1993, 118, 52416q.
12. Ikezaki, K.; Yamaguchi, T.; Miyazaki, C.; Ueda, H.; Kishie, T.; Tahara, Y.; Hiroyasu, K.; Takahashi, T.; Fukawa, H.; Komiyama, S.; Kuwano, M. Potentiation of anticancer agents by new synthetic isoprenoids. I. Inhibition of the growth of cultured mammalian cells. J. Natl. Cancer Inst. 1984, 73, 895-901.
13. Yamaguchi, T.; Ikezaki, K.; Kishiye, T.; Tahara, Y.; Koyama, H.; Takahashi, T.; Fukawa, H.; Komiyama, S.; Akiyama, S.; Kuwano, M. Potentiation of anticancer agents by new synthetic isoprenoids. II. Inhibition of the growth of transplantable murine tumors. J. Natl. Cancer Inst. 1984, 73, 903-907.
14. Nakagawa, M.; Akiyama, S.; Yamaguchi, T.; Shiraishi, N.; Ogata, J.; Kuwano, M. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. Cancer Res. 1986, 46, 4453-4457.
15. Yamaguti, T.; Nakagawa, M.; Shiraishi, N.; Yoshida, T.; Kiyosue, T.; Arita, M.; Akiyama, S.; Kuwano, M. Overcoming drug resistance in cancer cells with synthetic isoprenoids. J. Natl. Cancer Inst. 1986, 76, 947-953.
16. Akiyama, S.; Cornwell, M. M.; Kuwano, M.; Pastan, I.; Gottesman, M. M. Most drugs that reverse multidrug resistance inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analogue. Mol. Pharmacol. 1988, 33, 144-147.
17. Akiyama, S.; Yoshimura, A.; Kikuchi, H.; Sumizawa, T.; Kuwano, M.; Tahara, Y. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells. Mol. Pharmacol. 1989, 36, 730-735.
18. Ogawa, O.; Kishi, I.; Tahara, Y.; Sugita, M. SDB-Ethylenediamine malate as anticancer activity potentiator. Eur. Pat. Appl. EP 355604 1990; Chem. Abstr. 1991, 114, 95153m.
19. Inomata, K.; Takahashi, T.; Inoue, H.; Yanai, M.; Yamazaki, H.; Suzuki, M.; Takasawa, T.; Kawamura, K.; Oshida, N.; Ikemoto, H.; Kishie, T. Preparation of terpene ethylenediamines as multidrug resistance inhibitors. Eur. Pat. Appl. EP 781552 1997; Chem. Abstr. 1997, 127, 121902.
20. Tahara, Y.; Komatsu, Y.; Koyama, H.; Kubota, R.; Yamaguchi, T.; Takahashi, T. Isoprenylamine derivatives and their pharmaceutical compositions. Fr. Demande FR 2505826 1982; Chem. Abstr. 1983, 98, 215838.
21. Tawara, Y.; Mishima, Y. Preparation of N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine. Japan Pat. JP 03/02150 1991; Chem. Abstr. 1991, 114, 247565.
22. Suzuki, H.; Tomida, A.; Nishimura, T. Cytocidal Activity of a synthetic isoprenoid, N-solanesyl-N,N′-bis-(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro. Jpn. J. Cancer Res. 1990, 50, 298-303.
23. Tomida, A.; Tatsuta, T.; Suzuki, H. Novel mechanism of N-solanesyl-N,N′-bis-(3,4-dimethoxybenzyl)ethylenediamine in potentiation of antitumor drug action on multidrug-resistant and sensitive Chinese hamster cells. Jpn. J. Cancer Res. 1991, 51, 127-133.
24. Tomida, A.; Suzuki, H. Synergistic effect in culture of bleomycingroup antibiotics and of N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine, a synthetic isoprenoid. Jpn. J. Cancer Res. 1990, 50, 1184-1190.
25. Akiyama, S.; Shiraishi, N.; Yoshimura, A.; Nakagawa, M.; Yamaguchi, T.; Shimada, T.; Kuwano, M. Enhancement by a synthetic isoprenoid of the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin. Biochem. Pharmacol. 1987, 36, 861-868.
26. Ogihara, A.; Aiba, K.; Shibata, H.; Inoue, K.; Horikoshi, N.; Hirano, A.; Yamazaki, H.; Yoshida, K.; Kuraishi, Y. An investigation of mechanisms of enhanced cytotoxicity of 5-fluorouracil by a synthetic isoprenoid for human colon cancer cell lines. Proc. Am. Assoc. Cancer Res. 1994, 35, abstract A1910.
27. Takahashi, Y.; Urade, M.; Kishimoto, H.; Arimoto, T.; Yanagisawa, T.; Yoshioka, W. Combined effect of bleomycin and SDB-ethylenediamine, a synthetic isoprenoid, on oral squamous carcinoma cell lines and transplantable nude mouse tumors. Gan To Kagaku Ryoho 1995, 22, 883-887.
28. Suga, K.; Watanabe, S.; Fujita, T.; Pan, T. P. N-Alkylation of primary and secondary amines by alkyl halides and lithium naphthalene. Bull. Chem. Soc. Jpn. 1969, 42, 3606-3609.
29. Baky, H.; Kirsten, E. B. Verapamil. In Pharmacological and Biochemical Properties of Drug Substances; Goldberg, D., Ed.; American Pharmaceutical Association: Washington, DC, 1981; Vol. 3, pp 226-261.
30. Leo, A. J. Relationship between partitioning solvent systems. In Biological Correlations - The Hansch Approach; Advanced Chemistry Series; American Chemical Society: Washington, DC, 1972; Vol. 114; pp 51-60.
31. Franke, U.; Munk, A.; Wiese, M. Ionization constants and distribution coefficients of phenothiazines and calcium channel antagonists determined by a pH-metric method, and correlation with calculated partition coefficients. J. Pharm. Sci. 1999, 88, 89-95.
32. Pearce, H. L.; Winter, M. A.; Beck, W. T. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul. 1990, 30, 357-373.
33. Deichman, G. I.; Topol, L. Z.; Kluchareva, T. E.; Matveeva, V. A.; Zakamaldina, T. A.; Uvarova, E. N.; Tatosyan, A. G. Clustering of discrete cell properties essential for tumorigenicity and metastasis. III. Dissociation of the properties in N-ras-transfected RSV-SR-transformed cells. Int. J. Cancer 1992, 51, 903-908.
34. Shtil, A.; Shushanov, A.; Moynova, E.; Stavrovskaya, A. Frequency of metastasis in Syrian hamster tumor cells selected for low levels of "typical" multidrug resistance. Exp. Toxicol. Pathol. 1994, 46, 257-262.
35. Minor, P. D.; Roscoe, D. H. Colchicine resistance in mammalian cell lines. J. Cell Sci. 1975, 17, 381-396.
36. Erokhina, M. V.; Shtil, A. A.; Shushanov, S. S.; Sidorova, T. A.; Stavrovskaya, A. A. Partial restoration of the actin cytoskeleton in transformed Syrian hamster fibroblasts selected for low levels of "typical"" multidrug resistance. FEBS Lett. 1994, 341, 295-298.
37. Beck, W. T.; Danks, M. K. Characteristics of multidrug resistance in human tumor cells. In Molecular and Cellular Biology of Multidrug Rresistance in Tumor Cells; Roninson, I. B., Ed.; Plenum Press: New York and London, 1991; pp 3-55.
38. Mossman, T. Rapid Colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
39. Alekseevskaya, O. D.; Anfimova, M. L.; Djuraeva, F. H.; Somova, O. V.; Stavrovskaya, A. A.; Stromskaya, T. P.; Shtil, A. A.; Eraiser, T. L. Alterations of embryo-specific protein expression in multidrug resistant tumor cells. Her. Cancer Res. Center Russ. Acad. Med. Sci. 1993, 2, 21-30 (in Russian).
40. Stromskaya, T. P.; Filippova, N. A.; Rybalkina, E. Yu.; Egudina, S. V.; Shtil, A. A.; Eliseenkova, A. V.; Stavrovskaya, A. A. Alterations in melanin synthesis in human melanoma cells selected in vitro for multidrug resistance. Exp. Toxicol. Pathol. 1995, 47, 157-166.
41. Twentyman, P. R.; Fox, N. E.; Wright, K. A.; Bleechen, N. M. Derivation and preliminary characterization of adriamycin resistant lines of human lung cancer cells. Br. J. Cancer 1986, 53, 529-537.
42. Chaudhary, P. M.; Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-94.
43. Mechetner, E. B.; Schott, B.; Morse, B. S.; Stein, W. D.; Druley, T.; Davis, K. A.; Tsuruo, T.; Roninson, I. B. P-Glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 12908-12913.
44. 8-THC analogues: Relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency. J. Med. Chem. 2000, 43, 59-70.
45. Igarashi, J.; Thatte, H. S.; Prabhakar, P.; Golan, D. E.; Michel, T. Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 12583-12588.
46. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155-199.
47. Komarov, P. G.; Shtil, A. A.; Holian, O.; Tee, L.; Buckingham, L.; Mechetner, E. B.; Roninson, I. B.; Coon, J. S. Activation of the LRP (lung resistance-related protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine. Oncol. Res. 1998, 10, 185-192.
48. Lehne, G.; De Angelis, P.; den Boer, M.; Rugstad, H. E. Growth inhibition, cytokinesis failure and apoptosis of multidrugresistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999, 13, 768-778.
49. Blagosklonny, M. V. Drug-resistance enables selective killing of resistant leukemia cells: Exploiting of drug resistance instead of reversal. Leukemia 1999, 13, 2031-2035.
50. Shtil, A. A.; Turner, J. G.; Durfee, J.; Dalton, W. S.; Yu, H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T-lymphocytes. Blood 1999, 93, 1831-1837.
51. Grigor'eva, N. Ya.; Avrutov, I. M.; Semenovsky, A. V.; Odinokov, V. N.; Akhunova, V. R.; Tolstikov, G. A. Synthons for the synthesis of acyclic polyisoprenoids from isomeric ethyl farnesoates. Bull. Acad. Sci. USSR, Div. Chem. Sci. 1979, 38, 353-359.
52. Nigmatov, A. G.; Serebryakov, E. P.; Yanovskaya, L. A. Improved procedure for producing geranyl esters of (4E/Z,8E)- and (4E/Z,8Z)-farnesylacetic acids. Khim.-Farm. Zh. 1987, 21, 854-858 (in Russian).
53. Lowry, O.; Rosebrough, N.; Farr, A.; Randall, R. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-270.